Spots Global Cancer Trial Database for Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
Official Title: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
Study ID: NCT05271630
Conditions
Study Description
Brief Summary: The purpose of the study is to determine outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post Autologous Stem Cell Transplant (ASCT).
Detailed Description: This non-interventional, cohort prospective research study will assess outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post ASCT.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Moffitt Cancer Center, Tampa, Florida, United States
Contact Details
Name: Doris Hansen, MD
Affiliation: Moffitt Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
